New Stock News | Jingyin Pharmaceutical's Hong Kong IPO Prospectus Invalid
Jingyin Pharmaceutical (also known as Sirius) submitted its Hong Kong stock prospectus on September 28, 2025, which expired after 6 months on March 28, 2026. At the time of submission, Goldman Sachs, Haitong International, and HSBC were its joint sponsors.
Jingyin Pharmaceutical (also known as Sirius) submitted its Hong Kong Stock Exchange prospectus on September 28, 2025, which expired after 6 months on March 28, 2026. Goldman Sachs, HAITONG INT'L, and HSBC were its joint sponsors at the time of submission.
The prospectus shows that Jingyin Pharmaceutical is a global clinical-stage biotechnology company dedicated to maximizing the clinical and commercial value of siRNA therapy. The company's strategic foundation is based on a combination of three potential blockbuster product pipelines, a proprietary siRNA technology platform, and a global partnership network, aiming to innovate the current treatment standards for chronic diseases by developing groundbreaking and best-in-class siRNA therapies for the significant unmet medical needs worldwide.
According to a Frost & Sullivan report, the global siRNA therapy market reached $2.4 billion in 2024, and is expected to grow to $50.3 billion by 2040, with a compound annual growth rate of 20.9%.
Related Articles
HK Stock Market Move | VOYAH AUTO (07489) surged more than 11% in the afternoon with over 15,000 new vehicles delivered in March, an almost 80% increase compared to the previous month.
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
HK Stock Market Move | VOYAH AUTO (07489) surged more than 11% in the afternoon with over 15,000 new vehicles delivered in March, an almost 80% increase compared to the previous month.
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
